Janux Therapeutics Inc (JANX) — 13F Holders Deep Dive (Q2 2026)

JANX ranks #3026 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

JANX is a top-conviction position for Prosight Management, LP — at 10.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in JANX belongs to Ra Capital Management, L.p., but the position matters far more to Prosight Management, LP, who has 10.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its JANX position for two straight quarters, increasing it by $37.9M to reach $94.2M today.

Orbimed Advisors LLC has trimmed its JANX position for two straight quarters, cutting it by $18.9M while still holding $8.1M.

JANX is up 1.1% today, and institutions have been net buyers of $160.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

JANX reported a net loss of $113.6M in its latest fiscal year.

• Not yet profitable — net loss of $113.6M in the latest fiscal year
• Revenue declined 5.6% year over year
• Net income declined year over year, from -$69.0M to -$113.6M
• Operating cash flow was negative, using $82.2M in cash
• Current ratio of 39.04x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range